Piper Jaffray analyst Joseph Catanzaro notes that Iovance Biotherapeutics provided "positive" updates from cohort 2 of lifileucel's melanoma study and LN-145's cervical cancer trial. The analyst notes that response rates continue to "impress" and importantly responses continue to look to be durable. Overall, a "very positive" update that Catanzaro thinks bodes well for upcoming discussions with the FDA on LN-145's regulatory path in cervical cancer. He reiterates an Overweight rating and $20 price target on the shares, as he views Iovance as the best-positioned cell therapy in solid tumors.